-
Mashup Score: 31Blood Biomarkers to Detect Alzheimer Disease - 8 month(s) ago
Dr. Gregg Day talks with Dr. Sebastian Palmqvist about the use of blood biomarkers to streamline the diagnostic workup and treatment of Alzheimer disease. Read the related article in . Disclosures can be found at .
Source: directory.libsyn.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 11Outcomes of Patients With MCI With Lewy Bodies or Alzheimer Disease - 9 month(s) ago
Dr. Jeff Ratliff talks with Dr. Calum Alexander Hamilton about the importance of tracking and managing patients with MCI, especially those with Lewy body pathology. Read the related article in . Disclosures can be found at .
Source: directory.libsyn.comCategories: General Medicine News, NeurologyTweet
-
Mashup Score: 0
This Viewpoint discusses how the design of the Centers for Medicare & Medicaid Services (CMS) registry could impact Medicare’s ability to evaluate whether monoclonal antibodies are reasonable and necessary for patients with Alzheimer disease and help physicians understand when the drug is most…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 3Eligibility for Anti-Amyloid Treatment - 2 year(s) ago
Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment. Read the related article in . Visit for associated article links.
Source: directory.libsyn.comCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 3New Partnership Announced to Help Families Impacted by SYNGAP1 - Practical Neurology - 2 year(s) ago
The SYNGAP1 Foundation, a nonprofit patient advocacy group dedicated to improving the lives of families affected by SYNGAP1 and related overlapping ne
Source: practicalneurology.comCategories: Latest Headlines, NeurologyTweet-
In @AI_TechNews, #AIRAscore, the #AI-based software developed by @AIRAmed_GmbH which uses MRI brain scans to detect volume changes associated with #AlzheimerDisease, FTD, and other dementias and neurologic conditions, has received @US_FDA 501(k) clearance. https://t.co/2tp3aDjNCL https://t.co/AMT41NlPYJ
-
-
Mashup Score: 2Neurology Video Journal Club: Cognitive Disorders | American Academy of Neurology Journals - 2 year(s) ago
Learn from experts in the field of neurology as they discuss Neurology journal articles in the Neurology Video Journal Club Cognitive Disorders Collection
Source: www.neurology.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 7Neurology Video Journal Club: Cognitive Disorders | American Academy of Neurology Journals - 2 year(s) ago
Learn from experts in the field of neurology as they discuss Neurology journal articles in the Neurology Video Journal Club Cognitive Disorders Collection
Source: www.neurology.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 1Risk of All-Cause Dementia, Alzheimer Disease, and Vascular Dementia in Breast Cancer Survivors - 2 year(s) ago
Background and Objectives Now more than two-thirds of cancer survivors are aged 65 years or older, but evidence about their long-term health is thin. Cancer and its treatments have been linked to accelerated aging, so there is a concern that aging cancer survivors have an increased risk of age-related diseases, including dementia. Methods We examined the risk of dementia among 5-year breast cancer survivors using a matched cohort study design. We included breast cancer survivors aged 50 years and older at diagnosis (n = 26,741) and cancer-free comparison participants (n = 249,540). Women eligible for inclusion in the study were those born 1935–1975 and registered in the Swedish Total Population Register between January 1, 1991, and December 31, 2015. We defined breast cancer survivors as women with an initial breast cancer diagnosis between 1991 and 2005 who survived 5 or more years after their first diagnosis. We assessed all-cause dementia, Alzheimer disease (AD), and vascular dement
Source: cp.neurology.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0Trial of Donanemab in Early Symptomatic Alzheimer Disease - 2 year(s) ago
This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
.@JAMA_current: Among patients with early symptomatic #AlzheimerDisease and amyloid and tau pathology, #donanemab treatment significantly slowed clinical progression at 76 weeks. #Amyloidosis #TRAILBLAZER-ALZ 2 Randomized Clinical Trial #placebo #outcomes https://t.co/XSfu0mF0EP https://t.co/GqhwZnIQgZ
-
-
Mashup Score: 1Trial of Donanemab in Early Symptomatic Alzheimer Disease - 2 year(s) ago
This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
Neurology Podcast: Dr. Gregg Day & Dr. Sebastian Palmqvist discuss the use of blood biomarkers to streamline the diagnostic workup & treatment of #AlzheimerDisease. Listen now: https://t.co/NTGcdCi857 Article: https://t.co/cQjjx0BklX @biofinder_study @SebastianPalmqv @GDay_Neuro https://t.co/IV90YutNCU